ON JANUARY 2006, France became sole user of BCG vaccine Statens Serum Institut (SSI) for tuberculosis vaccination. Not long after, rapid increase in cases of adverse reactions (ADRs) came up; such as abscesses (in 73 percent of patients treated), around 30 percent had local reactions (lymphadenopathy of above one cm in size), while 20 patients developed suppurative lymphadenopathy.
Christelle Chol, leader of those who followed the patients for two years, found that the ADRs became consistent a year after their appearance or detection. They published their findings at the Pharmacoepidemiology and Drug Safety (Dec 5).
BCG vaccine—or Bacillus Calmette-Guerin (named after its discoverers)—contains weakened but alive strain of Mycobacterium bovis (a strain found in pigs). Because the bacteria can still stimulate reaction from a person’s immune system (without causing disease), it prepares the body to combat and destroy tuberculosis bacteria upon exposure. Studies in 1994 to 1995 showed a protective rate of 60 to 80 percent.
A clinical trial (1966) in the United States (Georgia and Alabama), however, showed only an efficacy of 14 percent. This figure left the authorities unconvinced in the use of BCG for mass vaccination there. Another trial (1979) in South India showed no efficacy at all.
And now we have these ADRs occurring in France. It might just be a case of contamination like what happened in 1930 (the first ever mass immunization using BCG also in France) where almost all of 240 infants immunized developed tuberculosis, resulting to 72 deaths. But this time, the French authorities believed that the ADRs came from the vaccine formulation itself.
The French problem is one of the many stories that highlight the dangers of synthetic medicines to health and life vis-Ã -vis their obvious accomplishments in chemotherapeutics. It tells of... [READ MORE]
This article appears in SunStar Cebu newspaper on 20 February 2013.
Comments
Post a Comment